BFRI Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$6.00median target· current $0.87 (+587.4%)2 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 13.00
EPS (TTM)$-0.430.0% YoY
Profit margin-13.8%HEALTHCARE
Market cap$13.8MMicro cap
Valuation
- Forward P/E
- 13.00
- PEG ratio
- —
- P/B
- 2.21
- P/S (TTM)
- 0.30
- EV/EBITDA
- -0.79
Profitability & growth
- ROE (TTM)
- -988.0%
- Operating margin
- -4.4%
- Revenue growth YoY
- 32.9%
- Dividend yield
- —
- Beta
- 0.88
Last earnings
Aug 13, 2026 · Estimate $-0.17 · Reported $-0.05
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Biofrontera Inc
Company profileBiofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 660 MAIN STREET, WOBURN, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$13.8M
Shares outstanding$14.9M
52W high$1.66
52W low$0.56
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent